(Reuters) - An Abbott spokeswomen said Xience, launched in Europe and Asia in October 2006, has captured a share of the market in the low double digits and expects to have market share in the mid-to-high 20 percent range by year end. She said Abbott is predicting similar success in the United States.
But the device will enter the U.S. market during tough times. Drug-coated, or drug-eluting, stents -- which have been very profitable for their manufacturers -- have been a source of controversy during the past year. While many doctors have turned to drug-eluting stents over bare metal stents because they tend to keep vessels clear whereas vessels with conventional bare metal stents often re-clog, the drug-eluting variety can carry a rare but potentially fatal risk for blood clots.
Read more at Reuters.com Business News
But the device will enter the U.S. market during tough times. Drug-coated, or drug-eluting, stents -- which have been very profitable for their manufacturers -- have been a source of controversy during the past year. While many doctors have turned to drug-eluting stents over bare metal stents because they tend to keep vessels clear whereas vessels with conventional bare metal stents often re-clog, the drug-eluting variety can carry a rare but potentially fatal risk for blood clots.
Read more at Reuters.com Business News
No comments:
Post a Comment